Uma Sharma, Ph.D. ’97, is the chief scientific officer for MMS Holdings Inc., headquartered in Canton, Mich.
After completing a doctorate degree in Pharmacology at the Wayne State University School of Medicine (she also attended the University of Michigan for her degree), Dr. Sharma went to work for Pfizer and its subsidiary, Parke-Davis, from 1998 to 2006. At Pfizer, she led the global development of Pregabalin for neuropathic pain and fibromyalgia. Pregabalin is now marketed in more than 100 countries.
Since 2006, Dr. Sharma has been the chief scientific officer at MMS Holdings Inc., where she leads a team of more than 400 colleagues located around the globe. MMS Holdings Inc. is a growing clinical research organization that focuses on regulatory submission support for the pharmaceutical industry and conducts associated clinical activities. Clients span from top 10 pharmaceutical companies to virtual biotechnology companies. Core service areas include medical and regulatory writing, biostatistics, clinical programming, data management, clinical development, clinical trial disclosure, regulatory affairs, regulatory submissions and pharmacovigilance. Under Dr. Sharma’s oversight, MMS has successfully submitted more than 50 new drug applications.
She also has participated in advisory boards for drug development and product defense strategies. She continues to be an invited speaker at national and international meetings.
Dr. Sharma continues to expand MMS Holdings Inc. by enforcing its mission to deliver high-quality services, rooted in sound science and decades of regulatory experience, thereby positively affecting patients’ lives worldwide.